Services

Nonclinical Safety Consulting Services

Nonclinical Safety Solutions provides expert toxicology consulting to support informed decision-making across all stages of drug development. Services are designed to identify, interpret, and manage safety risks while aligning nonclinical strategies with regulatory expectations. From early discovery guidance through IND-enabling programs and global submissions, NCSS delivers clear, science-driven insight to help advance therapeutic candidates with confidence.

Nonclinical Safety Strategy & Expert Toxicology Consulting

Precision toxicology guidance to design, evaluate, and strengthen nonclinical safety programs from early development through clinical entry, grounded in scientific interpretation and regulatory alignment.

Due Diligence Reviews, Impurity Assessments & Safety Liability Identification

Independent scientific diligence to identify safety liabilities, evaluate impurity risk, and inform confident, data-driven development and investment decisions.

Preclinical Study Planning, Design & GLP / Non-GLP Oversight

Strategic study planning and expert scientific oversight to ensure nonclinical programs are well-designed, appropriately scoped, and fully aligned with regulatory expectations.

Regulatory Strategy, Risk Assessment & Gap Resolution

Proactive regulatory insight to identify risks early, address critical data gaps, and build a defensible nonclinical strategy that supports efficient agency interactions.

Regulatory Submission Authoring for IND, NDA, BLA & MAA

Clear, cohesive, regulator-ready nonclinical narratives developed with direct insight into how FDA and global health authorities evaluate safety data.

Safety Pharmacology, ADME & PK / TK Interpretation

Integrated interpretation of pharmacology, ADME, and PK/TK data to support exposure-based safety justifications, starting-dose rationale, and clinical translation.

Specialized Toxicology Strategies for Oncology, Biologics & Advanced Modalities

Tailored nonclinical safety strategies addressing the unique challenges of oncology programs, biologics, imaging agents, and other complex therapeutic modalities where standard approaches may not apply.